Hepatitis C physical examination
Hepatitis C |
Diagnosis |
Treatment |
Hepatitis C physical examination On the Web |
American Roentgen Ray Society Images of Hepatitis C physical examination |
Risk calculators and risk factors for Hepatitis C physical examination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Patients with hepatitis C typically have a normal physical exam. In patients with advanced disease, physical exam signs of liver cirrhosis may be apparent.
Physical Exam
Patients with acute and chronic hepatitis C usually have a normal physical exam. Patients with more advanced disease manifest findings observed in patients with liver cirrhosis. A complete physical exam is important to assess patients with hepatitis C to guide the optimal choice of therapy.
Physical Exam | Comments |
Abdomen | Evidence of hepatic inflammation or hepatomegaly, signs of cirrhosis may be present including ascites (shifting dullness), splenomegaly, and caput medusae |
Cardiovascular system | Underlying cardiovascular disease may affect the choice of therapy. CVD is a relative contraindication to treatment with the combination of pegylated interferon and ribavirin. |
Extremities | Peripheral pitting edema can be a sign of portal hypertension. |
General appearance | Malnutrition can be a sign of advanced liver disease. |
HEENT | Thyroid abnormalities; treatment can cause or exacerbate autoimmune thyroiditis. |
Icterus | |
Mental status | Evidence of psychosis or depression, which are important contraindications to treatment. |
Respiratory system | Perform a general examination to exclude respiratory disease. |
Skin | Signs of alcohol abuse or liver failure, such as spider angioma, dilated veins over the chest or abdomen (indicative of portal hypertension), and palmar erythema. |
Jaundice and gynecomastia. | |
Cutaneous complications of long-term HCV infection, such as palpable purpura (associated with cryoglobulinemia) or blisters and vesicles, associated with porphyria cutanea tarda | |
Weight | Weight determines the dosage of pegylated interferon and ribavirin |
Adapted from Ward RP, Kugelmas M, Libsch KD. Management of hepatitis C: evaluating suitability for drug therapy. Am Fam Physician. 2004;69(6):1429-36.
References
- ↑ Ward RP, Kugelmas M, Libsch KD (2004). "Management of hepatitis C: evaluating suitability for drug therapy". Am Fam Physician. 69 (6): 1429–36. PMID 15053407.